Neurobiological Technologies, Inc.
NTII · OTC
9/30/2009 | 6/30/2009 | 3/31/2009 | 12/31/2008 | |
|---|---|---|---|---|
| Revenue | $6 | $16 | $3 | $3 |
| % Growth | -63% | 440.4% | -13.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6 | $16 | $3 | $3 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | -$0 | $2 | $10 |
| G&A Expenses | $1 | $1 | $1 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $3 | $12 |
| Operating Income | $5 | $15 | -$0 | -$8 |
| % Margin | 85.4% | 92.7% | -9.4% | -232.1% |
| Other Income/Exp. Net | $0 | -$15 | $0 | $8 |
| Pre-Tax Income | $6 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $5 | $14 | -$0 | -$8 |
| % Margin | 89.7% | 86.9% | -14.3% | -224.5% |
| EPS | 0.2 | 0.526 | -0.02 | -0.29 |
| % Growth | -62% | 2,728.3% | 93.1% | – |
| EPS Diluted | 0.2 | 0.525 | -0.02 | -0.29 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $5 | $15 | -$0 | -$8 |
| % Margin | 85.7% | 90.6% | -8.6% | -230.9% |